Humacyte Inc

HUMANASDAQ · USD
0.58USD0.00 (+0.90%)
122

Humacyte Inc (HUMA) Implied Volatility Current

HUMA implied volatility is 204%. IV Rank is 57%, placing current premiums in the middle of their 52-week range.

Read more

Tracking HUMA implied volatility helps you identify when options premiums on Humacyte Inc are historically cheap or expensive, and where the best trades are hiding. Humacyte Inc implied volatility reflects the market's expectation of future price movement: when HUMA IV rises, option premiums increase, creating opportunities for sellers, and when it drops, buyers can find cheaper contracts. Use our scanner to monitor Humacyte Inc's implied volatility current levels in real time and filter for high-probability trades.

Implied volatility is derived from option prices using models like Black-Scholes and represents the annualized expected move of an underlying stock. For HUMA, tracking metrics like HUMA IV rank helps traders understand whether current implied volatility is historically high or low. IV rank compares today's reading against the past year's range — a high rank on HUMA signals rich premiums and potential mean-reversion, while a low rank may favor long options strategies.

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes.

The company was founded in 2004 and is headquartered in Durham, North Carolina.

Premium sellers, directional traders, and spread builders all need the same starting point: a clear read on where HUMA implied volatility sits today versus where it has been. Our scanner ranks Humacyte Inc implied volatility against its historical range, surfaces extremes in HUMA IV rank, and pairs every reading with the trades that exploit it. Stop guessing whether Humacyte Inc IV is rich or cheap — measure it, then act on it.

Implied Volatility

IV Rank
57.14%IV Rank
Moderate

IV is slightly elevated - premiums are richer, leaning toward sellers.

Implied Volatility (30d)203.98%

IV Rank57.14%

Historical Volatility (30d)109.99%

IV - HV+93.99%

As of September 17, 2026

Trade options with IV on your side

Track HUMA IV rank across every expiration, spot where volatility is elevated, and identify high-probability setups before the window closes.

Start your 14-day free trial